azelnidipine has been researched along with deoxyguanosine in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Inoue, T; Kawagoe, Y; Koide, H; Nakamura, T; Node, K; Sugaya, T; Suzuki, T; Ueda, Y | 1 |
| Ito, S; Mori, T; Nako, K; Ogawa, S | 1 |
| Fujiwara, N; Inoue, T; Kawagoe, Y; Koide, H; Nakamura, T; Node, K; Sugaya, T; Ueda, Y | 1 |
| Inoue, T; Komoda, H; Node, K | 1 |
3 trial(s) available for azelnidipine and deoxyguanosine
| Article | Year |
|---|---|
Azelnidipine reduces urinary protein excretion and urinary liver-type fatty acid binding protein in patients with hypertensive chronic kidney disease.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Amlodipine; Antioxidants; Azetidinecarboxylic Acid; Blood Pressure; Calcium Channel Blockers; Deoxyguanosine; Dihydropyridines; Fatty Acid-Binding Proteins; Female; Heart Rate; Humans; Hypertension; Kidney Failure, Chronic; Male; Middle Aged; Proteinuria | 2007 |
Combination therapy with renin-angiotensin system inhibitors and the calcium channel blocker azelnidipine decreases plasma inflammatory markers and urinary oxidative stress markers in patients with diabetic nephropathy.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Azetidinecarboxylic Acid; C-Reactive Protein; Calcium Channel Blockers; Creatinine; Deoxyguanosine; Diabetic Nephropathies; Dihydropyridines; Dinoprost; Drug Therapy, Combination; Female; Humans; Interleukin-6; Male; Middle Aged; Oxidative Stress | 2008 |
Additional renoprotective effects of azelnidipine combined with angiotensin receptor blockers in patients with diabetic nephropathy.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Angiotensin II Type 1 Receptor Blockers; Azetidinecarboxylic Acid; Calcium Channel Blockers; Creatinine; Deoxyguanosine; Diabetic Nephropathies; Dihydropyridines; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fatty Acid-Binding Proteins; Female; Follow-Up Studies; Humans; Kidney; Male; Middle Aged; Treatment Outcome | 2008 |
1 other study(ies) available for azelnidipine and deoxyguanosine
| Article | Year |
|---|---|
Anti-inflammatory properties of azelnidipine, a dihydropyridine-based calcium channel blocker.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Atherosclerosis; Azetidinecarboxylic Acid; Biomarkers; C-Reactive Protein; Calcium Channel Blockers; Deoxyguanosine; Dihydropyridines; Female; Humans; Hypertension; In Vitro Techniques; Inflammation Mediators; Interleukin-6; Interleukin-8; Leukocytes, Mononuclear; Male; Middle Aged; Oxidative Stress | 2010 |